Equitable Holdings Inc. raised its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 16,854 shares of the medical research company’s stock after acquiring an additional 570 shares during the quarter. Equitable Holdings Inc.’s holdings in Edwards Lifesciences were worth $2,183,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Liberty Wealth Management LLC grew its position in shares of Edwards Lifesciences by 362.3% during the third quarter. Liberty Wealth Management LLC now owns 245 shares of the medical research company’s stock worth $29,000 after buying an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Northwest Investment Counselors LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Arlington Partners LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $34,000. Finally, Mascoma Wealth Management LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $38,000. 82.54% of the stock is owned by institutional investors.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,050 shares of the firm’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $123.34, for a total value of $1,362,907.00. Following the completion of the sale, the vice president now directly owns 152,326 shares of the company’s stock, valued at $18,787,888.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 20,000 shares of Edwards Lifesciences stock in a transaction on Friday, February 18th. The shares were sold at an average price of $106.31, for a total value of $2,126,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 250,031 shares of company stock valued at $26,973,194. 1.29% of the stock is currently owned by corporate insiders.
Edwards Lifesciences (NYSE:EW – Get Rating) last announced its quarterly earnings data on Tuesday, April 26th. The medical research company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.02. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the prior year, the business earned $0.54 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.
Several research firms have recently commented on EW. William Blair restated an “outperform” rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Piper Sandler decreased their price objective on Edwards Lifesciences from $133.00 to $125.00 in a research note on Thursday, January 27th. UBS Group raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $121.00 to $126.00 in a research note on Wednesday, February 2nd. Stifel Nicolaus decreased their price target on Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, January 27th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $132.00 to $135.00 in a report on Wednesday, March 16th. Five equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Buy” and a consensus target price of $127.50.
Edwards Lifesciences Company Profile (Get Rating)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.